Key result
Transaxillary sutureless AVR enables successful valve replacement with a ~34-minute cross-clamp time.
Case Report (n=1)
No
Transaxillary aortic valve replacement utilizing a sutureless bioprosthesis is a feasible minimally invasive alternative to sternotomy for treating severe aortic stenosis in comorbid patients, potentially shortening bypass and cross-clamp times.
May be feasible in multimorbid patients; leaves open comparative efficacy versus conventional approaches.
Clinical vignetteWe report the case of a 70-year-old man who presented with exertional dyspnea, New York Heart Association (NYHA) functional class II.Transthoracic echocardiography demonstrated severe aortic valve stenosis, with an aortic valve area of 0.7 cm 2 and grade I regurgitation on a markedly sclerotic valve.Coronary angiography revealed two-vessel disease (right coronary artery 50%, left anterior descending artery 60%, first diagonal branch 50%); all lesions were angiographically intermediate.The patient reported no angina.His medical history included implantation of a dual-chamber pacemaker in April 2026 for intermittent third-degree atrioventricular block.Relevant comorbidities comprised arterial hypertension, insulin-treated type 2 diabetes mellitus, chronic kidney disease stage 3, and peripheral arterial disease with prior percutaneous transluminal angioplasty and drug-eluting balloon angioplasty of the left superficial femoral artery.
No takes yet. Share an insight, caveat, or question.
Mohammad et al. (2026) conducted a case report in Severe aortic valve stenosis (n=1). Transaxillary aortic valve replacement with a sutureless bioprosthesis (Perceval Plus) was evaluated. Transaxillary aortic valve replacement with a sutureless bioprosthesis was successfully performed in a 70-year-old multimorbid man, resulting in a short cross-clamp time of 34 minutes and discharge on postoperative day 6.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: